Browse Drug Recalls
218 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 218 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 218 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jan 4, 2017 | Donepezil HCl tablets, 10mg, packaged in 10x10 blister packs per carton (100 ... | Supotent: Out of Specification result for assay test during routine stability testing. | Class III | Mckesson Packaging Services |
| Sep 15, 2016 | Xanax (Alprazolam) USP, CIV, 0.5 mg tablets , 10 x 10 blister cards per carto... | Labeling: Missing Label-Primary packaging label (i.e. blister card) is blank and contains no prod... | Class III | Mckesson Packaging Services |
| Sep 8, 2016 | Lansoprazole Delayed-Release Capsules, USP, 30 mg, packaged in 100-count cart... | Labeling: Label mix-up. The inner packaging was properly labeled Omeprazole DR 40mg Capsules, but... | Class III | Mckesson Packaging Services |
| Apr 12, 2016 | SKY Aspirin Chewable Tablets, 81 mg, Unit Dose 750 tablets (25 x 30) box, OTC... | Labeling: Label mix-up -outer carton incorrectly labeled as aspirin chewable tablets. | Class III | Mckesson Packaging Services |
| Jan 8, 2016 | Guaifenesin DM Cherry liquid (guaifenesin 100 mg/5 mL and Dextromethorphan HB... | Defective Delivery System: Firm recalled Guaifenesin liquid and Guaifenesin DM liquid due incorre... | Class II | Perrigo Company PLC |
| Oct 13, 2015 | Donnatal (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine H... | Labeling: Not elsewhere classified - Product label incorrectly lists Scopolamine Hydrocodone as a... | Class III | Rx PAK |
| Jul 28, 2015 | Health Mart Pharmacy loratadine orally disintegrating tablets, USP, 10 mg, 10... | Superpotent Drug: Out Of Specification (OOS) result for Assay. | Class III | Ohm Laboratories, Inc. |
| Jul 28, 2015 | Sunmark loratadine Orally Disintegrating Tablets, USP, 10 mg, packaged in a) ... | Superpotent Drug: Out Of Specification (OOS) result for Assay. | Class III | Ohm Laboratories, Inc. |
| Dec 4, 2014 | Eye Drops (Tetrahydrozoline HCl 0.05%), 0.5 FL OZ (15 mL) Bottles, Over the C... | CGMP Deviations: Active Pharmaceutical Ingredient (API) used for manufacture was stored in a non-... | Class III | K C Pharmaceuticals Inc |
| Dec 4, 2014 | Eye Drops Advanced Relief (Dextran 70 0.1%, Polyethylene glycol 400 1%, Povid... | CGMP Deviations: Active Pharmaceutical Ingredient (API) used for manufacture was stored in a non-... | Class III | K C Pharmaceuticals Inc |
| Sep 12, 2014 | Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, R... | Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled roo... | Class II | Mckesson |
| Jul 30, 2014 | Alprazolam Tablets, USP 0.25 mg, UD 100 Tablets (10 x 10), Rx Only, Mfg By: S... | Presence of Foreign Substance; tablets may contain stainless steel metal particulates | Class II | Mckesson Packaging Services |
| Jun 19, 2014 | Aspirin DR Enteric Coated Tablets, USP 325 mg, UD 750 tablets (25x30), Dist. ... | Failed Dissolution Specification; at the 12 month time interval. | Class III | Mckesson Packaging Services |
| Mar 3, 2014 | Venlafaxine Hydrochloride, Extended Release Capsules, 150 mg, UD-100 Tablets ... | Failed Dissolution Specification: Out of Specification dissolution results at 12 month interval. | Class III | McKesson Packaging Services |
| Feb 7, 2014 | Non-Drowsy 24 Hour Formula Allergy Relief and Nasal Decongestant, Pseudoephed... | Defective Container: An unacceptable level of blister defects have been identified in Loratadine ... | Class II | Ohm Laboratories, Inc. |
| Nov 1, 2013 | Acetaminophen suspension liquid, 160 mg/5 mL, cherry flavor, 2 FL OZ (59 mL) ... | Defective Delivery System: There is a remote potential that cartons of product could be co-packag... | Class II | L. Perrigo Co. |
| Mar 29, 2012 | buPROPion Hydrochloride Extended-Release Tablets (XL), 150 mg, UD 100 Tablets... | Failed USP Dissolution Test Requirements: Possible out-of-specification dissolution results at th... | Class III | McKesson Packaging Services |
| Mar 29, 2012 | buPROPion Hydrochloride Extended-Release Tablets (XL), 300 mg, UD 100 Tablets... | Failed USP Dissolution Test Requirements: Possible out-of-specification dissolution results at th... | Class III | McKesson Packaging Services |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.